ArticleCancer medicine2022

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study.

Yuchen Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.